We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Illumina Inc. is another one of the best cancer stocks on our list.
TheFly reported on January 7 that TD Cowen raised its price target on ILMN to $140 from $115 while maintaining a Hold rating. The change was included in the company’s outlook for the life science tools industry for the fourth quarter. Although several firms have already released cautious advice for 2026, the analyst pointed out that recent share price advances have elevated expectations. TD Cowen feels this leaves space for upside next year.
Separately, on January 6, Illumina Inc. (NASDAQ:ILMN) launched Illumina Connected Multiomics, a cloud-based platform designed to integrate and analyze large multiomic datasets.
Illumina Inc. (NASDAQ:ILMN) develops advanced genomic sequencing and multiomics solutions, enabling precision oncology research, biomarker discovery, and targeted therapies. Its AI-driven platforms accelerate cancer diagnostics, drug development, and personalized treatment strategies, positioning the company as a leader in oncology-focused genomic innovation.
While we acknowledge the potential of ILMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.
Disclosure: None.
